Eleven Biotherapeutics, Inc. (EBIO) saw a big move in the last trading session, as the company’s shares fell by nearly 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent trend for EBIO, as the stock is now down over 15% since Feb 23.
This slump shouldn’t be too much of a surprise to investors, as the clinical-stage biopharmaceutical company has seen 1 negative revision in the past few weeks and its current year loss consensus has also widened over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
EBIO currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Investors interested in the Medical – Biomedical/Genetics industry may consider a better-ranked stock like Acorda Therapeutics, Inc. (ACOR), carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report
ACORDA THERAPT (ACOR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research